BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//International Health Economics Association - ECPv6.16.3//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://healtheconomics.org
X-WR-CALDESC:Events for International Health Economics Association
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20250101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:UTC
BEGIN:STANDARD
TZOFFSETFROM:+0000
TZOFFSETTO:+0000
TZNAME:UTC
DTSTART:20250101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VTIMEZONE
TZID:America/Toronto
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20270314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20271107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=UTC:20260409T070000
DTEND;TZID=UTC:20260409T080000
DTSTAMP:20260609T115304
CREATED:20260305T182347Z
LAST-MODIFIED:20260305T182347Z
UID:334784-1775718000-1775721600@healtheconomics.org
SUMMARY:Showcasing ECR Research in Health Economics: BRCA Screening Webinar
DESCRIPTION:Add to Calendar! \nThis webinar will feature presentations from Dr Xia Wei (Postdoctoral Researcher\, Peking University)and Mackenzie Bourke (PhD Candidate and Research Fellow\, University of Melbourne). They will present their research on the economic evaluation of BRCA screening strategies\, including implications for prevention policy and resource allocation. \nEconomic evaluation of genetic testing and management strategies for breast and ovarian cancer\nThis presentation will present cost-effectiveness evidence on genetic testing and management strategies for breast and ovarian cancer. It will cover economic evaluations of unselected and population-based genetic testing\, and gene-specific prevention options (including cancer screening\, medical prevention\, and risk-reducing surgery) across different risk groups and settings. The analysis considers long-term health outcomes\, costs\, and quality-of-life impacts\, and discusses the implications for management pathways and resource allocation decision-making for breast and ovarian cancer. \nIntegrating individual-level preferences into an economic evaluation of genomic screening\nSuccessful implementation of genomic screening for the management of breast and ovarian cancer depends on uptake of genetic testing\, preventative therapies\, and intensified surveillance programs. Where economic evaluations have incorporated patient preferences\, these have typically been applied inconsistently and primarily at the cohort level. This study integrates discrete choice experiment data within a discrete-event simulation to predict individual-level preferences and estimate their impact on costs and health outcomes. Preliminary results suggest that incorporating individual preferences has only a marginal impact on average cost-effectiveness outcomes\, but a larger effect on subgroup-level cost-effectiveness results\, which may have important distributional implications. \nSpeakers:  \nXia Wei – Postdoctoral fellow\, School of Public Health\, Peking University\nXia Wei is a postdoctoral fellow at the School of Public Health\, Peking University. She received her PhD from the London School of Hygiene & Tropical Medicine. Her research focuses on health economics\, health technology assessment\, and evidence-based decision-making in cancer prevention and control. She has published more than 26 full-text publications in peer-review journals\, including JAMA Oncology and JAMA Network Open. \n  \n  \n  \n  \nMackenzie Bourke – PhD Candidate\, Economics of Genomics and Precision Medicine Unit\, University of Melbourne\nMac is a PhD candidate and research assistant in the Economics of Genomics and Precision Medicine Unit at the Melbourne School of Population and Global Health\, University of Melbourne. His research focuses on the economic modelling of genomic technologies for cancer and on advancing methodological approaches to better capture the value of genomic medicine in health economic evaluation. His work also examines quality-of-life outcomes among people living with rare conditions and their careers\, with the aim of improving how these impacts are measured and incorporated into economic evaluations and policy decisions relating to genomic and precision medicine.
URL:https://healtheconomics.org/event/showcasing-ecr-research-in-health-economics-brca-screening-webinar/
LOCATION:Zoom
CATEGORIES:IHEA Event
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20260413T153000
DTEND;TZID=UTC:20260413T163000
DTSTAMP:20260609T115304
CREATED:20260402T144334Z
LAST-MODIFIED:20260402T153005Z
UID:334843-1776094200-1776097800@healtheconomics.org
SUMMARY:Culture and Health
DESCRIPTION:Add to Calendar! \nThis webinar explores the multifaceted relationship between culture and health from an economic perspective\, integrating insights from anthropology\, psychology\, and political science. It begins by examining how culture provides meaning to illness and suffering and explores how culturally grounded “disease theory systems” influence beliefs about what causes illness\, how and whether suffering should be remedied\, and the appropriate role of the state in allocating health care resources. The importance of culture in defining the boundary between normal and abnormal pathology is highlighted via case studies. The chapter next reviews evidence on how health behaviors such as smoking\, firearm ownership\, dietary practices\, and reproductive decisions are influenced by cultural norms of masculinity and religiosity. Lastly\, it examines how firms\, governments\, and civil society leverage and advance cultural narratives to influence individual behavior and public policy. Thus\, culture in relation to health both naturally evolves and is actively constructed\, with implications for health inequality and health policy. \nSpeaker:  \nMarcella Alsan is a physician-economist studying the economics of health inequality domestically and internationally. She is Associate Editor at the Journal of Economic Literature and Co-Chair of the Health Care Delivery Initiative of Abdul Latif Jameel Poverty Action Lab at MIT. She is co-recipient of the 2019 Arrow Award for Best Paper in Health Economics\, the 2021 William G. Manning Memorial Award for the Best Research in Health Econometrics\, recipient of a MacArthur Fellowship and was elected into the National Academy of Medicine in 2022. She co-directs the Health Inequality Lab at Harvard Kennedy School of Government.
URL:https://healtheconomics.org/event/culture-and-health/
LOCATION:Zoom
CATEGORIES:IHEA Event
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20260428T140000
DTEND;TZID=UTC:20260428T150000
DTSTAMP:20260609T115304
CREATED:20260402T152906Z
LAST-MODIFIED:20260407T180713Z
UID:334848-1777384800-1777388400@healtheconomics.org
SUMMARY:A new approach to comparing EQ-5D-5L value sets: What really makes a difference to people?
DESCRIPTION:Add to Calendar! \nBackground\nEQ-5D-5L value sets play a vital role worldwide in health technology assessment and measuring population health. However\, it is difficult to compare the impact of using different value sets\, for example if an older value set is replaced by a new one\, or if two or more value sets are available. \nObjectives\n1) Reformulating the standard EQ-5D-5L health-state utility model in terms of meaningful\, interpretable parameters: range of utility from best to worst state\, relative importance of each dimension\, and decrements associated with levels 2-4 as a fraction of the level 5 decrement;\n2) Providing formulae for the marginal effects of the reformulated model’s parameters on utilities;\n3) Empirically estimating marginal effects for several value sets and patient groups. \nData and Methods\nThe 2017/8 Health Surveys for England collected EQ-5D-5L responses from around 13\,000 people. Participants with a long-term condition were divided into patient groups according to how the condition affected them (vision/mobility/mental health/etc.). Participants with long-lasting pain were divided into groups of varying severity using the Chronic Pain Grade Scale (CPGS). The marginal effects of parameters from 48 EQ-5D-5L value sets were calculated for each patient group. In countries with multiple value sets available\, differences in parameters were compared to differences in mean utility. \nResults\nParameters representing value set range had consistently large marginal effects across value sets and patient groups. Increased importance of self-care relative to other dimensions always increased utility\, though with variable effect sizes. The direction and magnitude of the marginal effects of other dimensions’ relative importance varied across value sets and patient groups. The magnitude of all parameters’ marginal effects increased with condition severity.\nIn within-country comparisons the magnitudes of parameter differences were related to utility differences\, with the smallest and largest differences for both seen when comparing the Japanese and Peruvian value sets respectively. Utility differences were increasing in disease severity: the utility of people with the worst chronic pain level differed by 0.425 depending on which Peruvian value set was used. \nConclusion\nThis study presents innovative methods for comparing EQ-5D-5L value sets and assessing what aspects have the biggest impact on patient utilities. Value set range was a major driver of utility differences\, and people with more severe conditions were most likely to be impacted by using alternative value sets. \nSpeaker: \nEd Webb is an associate professor at the Academic Unit of Health Economics\, University of Leeds. He studies preferences and decision-making in a wide variety of contexts and using a range of methods. His other research interests include the measurement and valuation of health\, as well as interactions between health\, work and wellbeing.
URL:https://healtheconomics.org/event/a-new-approach-to-comparing-eq-5d-5l-value-sets-what-really-makes-a-difference-to-people/
LOCATION:Zoom
CATEGORIES:IHEA Event
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20260504T153000
DTEND;TZID=UTC:20260504T163000
DTSTAMP:20260609T115304
CREATED:20260423T162906Z
LAST-MODIFIED:20260423T163130Z
UID:335019-1777908600-1777912200@healtheconomics.org
SUMMARY:Do GLP-1 Medications Pay for Themselves?
DESCRIPTION:Add to Calendar! \nGlucagon-like peptide-1 receptor agonists (GLP-1s) represent a major improvement in treatment of diabetes\, obesity\, and cardiovascular risk reduction\, but they are also among the most expensive drugs in widespread use and the subject of significant policy debate. The high price of these drugs may overstate their net cost if the health improvements they produce lead to reduced downstream health care use and medical spending\, that is\, cost offsets. We estimate such offsets using insurance claims data\, examining the effects of GLP-1 initiation on subsequent GLP-1 use and spending\, and on other non-GLP-1 spending. We use a stacked difference-in-differences design\, comparing patients initiating GLP-1 medication to not-yet-treated controls who initiate GLP-1s several months or years later\, allowing us to control for underlying time trends and baseline characteristics. Overall\, we do not find a reduction in downstream medical spending. Although GLP-1 initiation reduces spending on other diabetes medications\, total non-GLP-1 spending increases\, driven by higher outpatient health care use; GLP- 1 drug spending rises mechanically. For health care payers\, the relevant cost of GLP-1 initiation therefore extends beyond the sticker price of the drug. We find similar results across subgroups of GLP1 initiators including those with prior cardiovascular disease and those without diabetes (consistent with obesity indication). Our main results examine spending responses over the first year after initiation. However\, we also estimate longer run effects in a smaller sample and find no cost offsets even five years after GLP-1 initiation. Taken together\, these results suggest that payers facing the costs of GLP-1 coverage are unlikely to see large savings from reduced spending on other care. If GLP-1 therapies ultimately yield cost savings\, they are likely to occur only over longer horizons or through non-medical channels. \nSpeaker: \nDr. Kosali Simon is the Herman B Wells Endowed Professor at Indiana University. In 2021\, she was elected to the National Academy of Medicine. Simon is a nationally known health economist who specializes in applying economic analysis in the context of health insurance and health care policy. Her current research mainly focuses on the impact of health insurance reform on healthcare and labor market outcomes\, and on the causes and consequences of the opioid crisis. She is also active in national leadership roles in her profession\, serving on several boards and in editorial positions. A summary of her recent research appears in the 2018 National\nBureau of Economic Research Reporter.
URL:https://healtheconomics.org/event/do-glp-1-medications-pay-for-themselves/
LOCATION:Zoom
CATEGORIES:IHEA Event
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20260505T143000
DTEND;TZID=UTC:20260505T153000
DTSTAMP:20260609T115304
CREATED:20260423T142813Z
LAST-MODIFIED:20260423T151309Z
UID:335013-1777991400-1777995000@healtheconomics.org
SUMMARY:Do changes in management practices reduce hospital waiting times? Evidence from a workforce retention programme
DESCRIPTION:Add to Calendar! \nLong before the pandemic\, increasingly longer waiting times for hospital treatment in English NHS has been a challenge\, directly affecting patient outcomes\, service efficiency\, and overall healthcare quality. In this paper\, we develop a theoretical model that links patients’ waiting times for planned treatment to hospital nurses’ retention\, and postulate the possibility of a virtuous loop between these two variables that can be ignited by higher managerial quality. We test these hypotheses by assessing the effects of a national workforce policy on waiting times\, leveraging a synthetic difference-in-difference analysis using detailed patient records for planned care admissions to English NHS hospitals.\nIn line with the predictions\, our results suggest that the policy had indeed improved nurses’ retention\, while also leading to reductions in average waiting times for planned knee replacement surgery and shortens waiting times for all planned procedures. Our results highlight the potential benefits of workforce stability and managerial improvements on healthcare delivery. \nSpeaker: \n \nGiuseppe is a Professor of Economics at the University of Surrey and an empirical economist specialising in health economics\, labour economics\, and applied micro-econometrics. He previously held research positions at the Centre for Health Economics\, University of York\, and before his PhD he has worked in investment banking at Lehman Brothers in London. Giuseppe earned his PhD in Econometrics and Empirical Economics from the University of Rome Tor Vergata\, following undergraduate and master’s degrees from Bocconi University in Milan. \nHis research focuses on generating robust causal evidence to inform health and workforce policy\, with particular expertise in provider choice and competition\, hospital performance\, waiting times\, health inequalities in access to healthcare\, and the economics of the healthcare workforce. From 2019 to 2025\, Giuseppe has been the Principal Investigator of a major Health Foundation–funded programme examining the determinants and impacts of hospital workforce retention in the English NHS. His work is widely published in leading health economics and social science journals.
URL:https://healtheconomics.org/event/do-changes-in-management-practices-reduce-hospital-waiting-times-evidence-from-a-workforce-retention-programm/
LOCATION:Zoom
CATEGORIES:IHEA Event
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20260513T120000
DTEND;TZID=UTC:20260513T140000
DTSTAMP:20260609T115304
CREATED:20260417T155858Z
LAST-MODIFIED:20260420T144300Z
UID:334964-1778673600-1778680800@healtheconomics.org
SUMMARY:Health spending and outcomes
DESCRIPTION:Add to Calendar! \nThis web workshop will explore the relationship between health spending and health outcomes\, bringing together empirical evidence from a diverse range of country contexts. Presentations will examine whether increased public investment in health translates into measurable improvements in population health\, drawing on case studies from Brazil\, Indonesia\, the United Kingdom\, the United States\, and South Africa\, alongside a systematic review of existing research. The session will provide participants with a deeper understanding of the key methods and theoretical approaches used to evaluate the impact of health expenditure. It will conclude with dedicated time for questions\, answers\, and open discussion\, offering an opportunity for critical reflection and exchange. \nPresentations: \n\n The effect of public health expenditure on health and health care use: a systematic review\n\n \nThis systematic review and meta-regression analysis synthesizes the international literature on the effect of public health expenditure on health and care. Findings highlight the importance of strong governance\, sustainable financing\, and investment in prevention and workforce\, while revealing key gaps in evidence from low- and middle- income countries and in understanding financing mechanisms. \n  \nPresenter: Eliana Chavarría-Pino is a postdoctoral researcher at the Ludwig Maximilian University of Munich. Her work focuses on the evaluation of health policies and programmes in low- and middle-income countries\, with a particular emphasis on health financing and the health workforce. \n  \n\n The impact of different types of NHS expenditure on health: Marginal cost per QALY estimates for England for 2016/17\n\nThis study examines how different types of NHS spending vary in their ability to generate health gains\, measured in cost per quality-adjusted life year (QALY). Using 2016 data and two-stage least squares\, the authors estimate that locally commissioned services deliver a QALY for around £8\,000\, while results for primary care and specialised services are more uncertain. Accounting for this variation slightly increases the overall estimated cost per QALY across the NHS. The findings suggest that directing additional investment toward primary care and locally commissioned services may yield the greatest health benefits. \nPresenter: James Lomas is a senior lecturer at the Department of Economics and Related Studies at the University of York. His research is focused on applied microeconometric analysis that answers the empirical questions posed in the context of economic evaluation and cost-effectiveness analysis.  \n  \n\n Health system efficiency under fiscal constraint: Spending complementarity and district performance in South Africa\n\n \nThis study evaluates how efficiently public health funds are used across 48 districts in South Africa amid tight fiscal constraints. Using stochastic frontier analysis\, it finds wide variation in efficiency (7%–87%)\, with significant potential to improve health outcomes without increasing spending. Results highlight that primary health care spending is most effective when supported by sufficient hospital capacity\, while hospital spending shows more consistent benefits. The study identifies district performance patterns to guide better resource allocation and peer learning in constrained health systems. \nPresenter: Fouché Venter is Executive Director of Economic Research Southern Africa and an applied economist focused on public economics. His research examines fiscal sustainability\, fiscal frameworks\, and the efficiency and effectiveness of public resource allocation. \n  \n\n Does Increasing Public Spending in Health Improve Health? Lessons from a Constitutional Reform in Brazil\n\nThis presentation discusses how government health spending shapes health outcomes by exploring unique top-down variation generated by Brazil’s 29th Constitutional Amendment\, which mandated minimum thresholds for municipal health spending. It describes how sharp changes in health spending resulting from the Constitutional Amendment affect downstream outcomes\, documenting increases in available resources and access to health at various margins\, with resulting declines in infant mortality and all cause mortality. Secondly\, it discusses the production function of public healthcare\, documenting non-linearities and input complementarities.  A number of key margins of spending effectiveness and constraints to larger gains from health spending are highlighted\, including frictions between bureaucratic capacity and political incentives. \nPresenter: Damian Clarke is a researcher and Associate Professor of Economics at The University of Exeter\, and The University of Chile. His research focuses on maternal and child health\, and family fertility decisions. In particular\, his papers examine the impact of public programs on maternal mortality and morbidity\, early life health outcomes for children\, and the determinants of parental investment in children. \n  \n\n Does increasing overall health expenditure reduce inequality in under-5 mortality rates between provinces in Indonesia?\n\nThis study analyses whether increased public health spending in Indonesia (2004–2012) reduced inequalities in under-five mortality across socioeconomic groups. Using dynamic panel System-GMM and instrumental variables\, it finds that higher spending actually widened inequality\, as wealthier households benefited more from mortality reductions than poorer ones. The study finds no significant difference in impact between provinces with high and low baseline mortality. Overall\, the results suggest that simply increasing health spending is insufficient to reduce inequalities unless funds are better targeted toward disadvantaged populations and high-need areas. \nPresenter: Ivan Ochoa-Moreno is a Research Fellow in Global Health at the University of York. His research focuses on impact evaluation of health policies\, universalisation of healthcare and lifelong impact of early-life health and development. \n  \n\n The Value of Healthcare in the United States: Changes in Lifetime Spending and Health-Adjusted Life Expectancy\, 1996 to 2016\n\nThis study extends prior work on the value of healthcare spending by examining health-adjusted life expectancy (HALE) and lifetime costs across all ages and diseases. Using global burden and expenditure data\, it estimates that healthcare improvements from 1996 to 2016 increased HALE by about 1.3 years at a cost of roughly $182\,000 per HALE gained. Results vary widely by disease\, with substantial gains for conditions like HIV/AIDS and heart disease\, but negative effects for drug use disorders. The findings highlight the importance of evaluating healthcare value across the full life course and by specific causes. \nPresenter: Marcia Weaver\, PhD\, is a Research Professor of Health Metrics Sciences at the Institute for Health Metrics and Evaluation (IHME) at the University of Washington where she leads the cost-effectiveness research team. She specialises in meta-regression analysis of published cost-effectiveness estimates and has published 103 peer-reviewed articles. 
URL:https://healtheconomics.org/event/health-spending-and-outcomes/
LOCATION:Zoom
CATEGORIES:IHEA Event
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20260519T133000
DTEND;TZID=UTC:20260519T143000
DTSTAMP:20260609T115304
CREATED:20260501T181349Z
LAST-MODIFIED:20260501T182108Z
UID:335072-1779197400-1779201000@healtheconomics.org
SUMMARY:Health Efficiency and Inequality
DESCRIPTION:Add to Calendar! \nIs the trade-off between health system efficiency and equity inevitable? This iHEA Health Efficiency SIG webinar brings together evidence from OECD countries (efficiency-equity dynamics)\, Chile (UHC fragmentation and new inequalities)\, and the US (public health impact of federal worker layoffs). \nHost: Simon Combes\, Lecturer in Health Economics\, UCL Global Business School for Health\, University College London \nThis session will feature three different presentations from the following speakers: \n \nQays Bousmah & Mohammad Abu-Zaineh (OECD health systems efficiency & equity)\nDo we need health systems to be more efficient or more equal? Evidence from OECD countries – https://www.sciencedirect.com/science/article/pii/S0277953625007105 \n  \n  \n \nMarcela González-Agüero\nEquality in healthcare access rights does not mean equality of access: Evidence from Chile (UHC fragmentation and new inequalities – Chile)\nhttps://anthrosource.onlinelibrary.wiley.com/doi/abs/10.1111/maq.12555 \n  \n  \nBenjamin Sommers\nIgnorance or incompetence? – Or both? When the US government lays off health workers\nhttps://jamanetwork.com/journals/jama-health-forum/fullarticle/2834686 \n 
URL:https://healtheconomics.org/event/health-efficiency-and-inequality/
LOCATION:Zoom
CATEGORIES:IHEA Event
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20260525T050000
DTEND;TZID=UTC:20260525T060000
DTSTAMP:20260609T115304
CREATED:20260420T172146Z
LAST-MODIFIED:20260420T172146Z
UID:334975-1779685200-1779688800@healtheconomics.org
SUMMARY:A 10-year scoping review: an inspirational or cautionary tale?
DESCRIPTION:Add to Calendar! \nEver started a project that was meant to be ‘quick and straightforward’? In this webinar\, Associate Professor Nikki McCaffrey will share the story behind a scoping review that took almost a decade to complete before publication in Social Science & Medicine. The talk offers a candid\, slightly irreverent look at scope creep\, opportunity cost\, and the hard calls around when to persist\, pivot\, or cut losses. Short\, honest\, and practical\, with reassurance that messy research journeys are far more common than we admit. \nSpeaker: \nAssociate Professor Nikki McCaffrey is a health economist at Deakin University\, Victoria\, Australia and Head of Cancer Economics. She works at the intersection of health economics\, outcomes research and policy\, with a particular focus on cancer\, palliative and end‑of‑life care\, and the often‑overlooked role of informal carers. Nikki has published 100+ peer‑reviewed papers and secured over $20 million in competitive research funding\, leading multidisciplinary teams across Australia and internationally. She is a co‑founder and co‑lead of the International Health Economics Association Special Interest Group on the Economics of Palliative & End‑of‑Life Care\, and is a strong advocate for applied\, decision‑relevant research that actually gets used.
URL:https://healtheconomics.org/event/a-10-year-scoping-review-an-inspirational-or-cautionary-tale/
LOCATION:Zoom
CATEGORIES:IHEA Event
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20260528T080000
DTEND;TZID=UTC:20260528T090000
DTSTAMP:20260609T115304
CREATED:20260325T193218Z
LAST-MODIFIED:20260526T183047Z
UID:334808-1779955200-1779958800@healtheconomics.org
SUMMARY:Biobanks and Genomics in Low- and Middle-Income Countries: Emerging Opportunities for Research and Health Economics Webinar & Panel Discussion
DESCRIPTION:📅 Add to Calendar!   |   🎥 Join Webinar on Zoom \nThis panel discussion will feature short presentations from Professor Segun Fatumo (Chair of Genomic Diversity at Queen Mary University of London and Head of Non-Communicable Disease Genomics at the MRC Uganda Research Unit) and Professor Zhu Chen (College of Economics and Management\, China Agricultural University\, Beijing). The speakers will highlight emerging opportunities in biobanks and genomics\, particularly in low- and middle-income country (LMIC) settings. The panel discussion will then explore how biobank and genomic platforms and data can be leveraged to inform health economic analysis and policy decision-making in LMICs\, followed by an open discussion and concluding remarks. \nModerator: Professor Zanfina Ademi\, Monash University \nPresentation 1:\nName: Professor Segun Fatumo\nRole & organization: Chair of Genomic Diversity at Queen Mary University of London and Head of Non-Communicable Disease Genomics at the MRC Uganda Research Unit\nBio: Professor Segun Fatumo is a globally recognised genomic epidemiologist advancing equitable human genomics research. He is Professor and Chair of Genomic Diversity at Queen Mary University of London and Head of Non-Communicable Disease Genomics at the MRC Uganda Research Unit. His work focuses on genetic determinants of cardiometabolic disease and kidney disease in diverse ancestry populations. He leads major initiatives including KidneyGenAfrica\, BCX-Africa and the Nigerian 100K Genome Project\, supported by international funders such as the MRC\, NIH and Wellcome Trust. Professor Fatumo is widely published\, serves on global advisory boards\, contributes to genomics policy and capacity building in Africa\, and is a frequent keynote speaker and media commentator\nAbstract: The Uganda Genome Resource (UGR) is a well-characterized genomic biobank derived from the long-standing Uganda General Population Cohort\, comprising genotype data (~5\,000 individuals) and whole-genome sequencing (~2\,000 individuals) across 10 ethno-linguistic groups. With rich phenotypic data spanning communicable and non-communicable diseases\, UGR provides a unique platform for advancing genomics\, multi-omics integration\, and precision medicine in African populations. It enables discovery of population-specific variants\, improved disease risk prediction\, and deeper biological insights across diverse ancestries. These opportunities position UGR as a critical resource not only for scientific discovery but also for generating evidence to inform cost-effective health economic strategies and policy decisions in LMICs. \nPresentation 2:\nName: Professor Chen Zhu\nRole & organization: College of Economics and Management\, China Agricultural University\, Beijing\nBio: Chen Zhu is a Professor at the College of Economics and Management\, China Agricultural University. She received her Ph.D. in Agricultural and Resource Economics from the University of Connecticut and her B.S. in Biology from Nanjing University. She currently serves as an Associate Editor for Agribusiness and an Editorial Board Member of Scientific Reports. Dr. Zhu has published more than 50 peer-reviewed articles in economics\, public health\, and interdisciplinary journals. Her research focuses on genoeconomics\, integrating genetic and socioeconomic data to better understand human capital formation\, health behaviors\, and economic decision-making\, with particular interest in applications to rural development and health policy in China. Website: https://zhuchencau.wordpress.com/cv/\nAbstract: This talk introduces a pilot Human Capital and Genoeconomics Survey conducted among rural households in China since 2019. The survey combines rich socioeconomic information\, including human capital\, health behaviors\, fertility\, and household decision-making\, with individual genetic data for about 800 participants in rural China. Using this dataset\, she will explore how genomic variation interacts with environmental conditions\, nutrition\, and local economic contexts to shape health and socioeconomic outcomes. She will argue that small- and medium-scale genomic surveys linked to detailed socioeconomic data can complement large biobanks\, offering a practical framework for advancing genoeconomics research and informing health and development policy in low- and middle-income country settings.
URL:https://healtheconomics.org/event/biobanks-and-genomics-in-low-and-middle-income-countries-emerging-opportunities-for-research-and-health-economics-webinar-panel-discussion/
LOCATION:Zoom
CATEGORIES:IHEA Event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260606
DTEND;VALUE=DATE:20260612
DTSTAMP:20260609T115304
CREATED:20251116T003732Z
LAST-MODIFIED:20251116T005959Z
UID:334343-1780704000-1781222399@healtheconomics.org
SUMMARY:ASHEcon 2026 Annual Conference
DESCRIPTION:
URL:https://healtheconomics.org/event/ashecon-2026-annual-conference/
CATEGORIES:External Event
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20260608T153000
DTEND;TZID=UTC:20260608T163000
DTSTAMP:20260609T115304
CREATED:20260528T170739Z
LAST-MODIFIED:20260528T171741Z
UID:335259-1780932600-1780936200@healtheconomics.org
SUMMARY:Weighing the Impacts of GLP-1s: Quasi-Experimental Evidence From Provider Adoption
DESCRIPTION:📅 Add to Calendar! |  🎥 Join Webinar on Zoom \nThe arrival of GLP-1 medications has been described as one of the most important healthcare innovations in recent years. In this webinar\, Jasmin Moshfegh (Imperial College Business School) will present large-scale quasi-experimental evidence on the real-world impacts of GLP-1 adoption. \nUsing comprehensive Veterans Health Administration data covering 1.4 million diabetic or obese veterans\, this study examines how variation in physicians’ prescribing propensities affects patient outcomes. The findings demonstrate substantial improvements in glycemic control and clinically meaningful weight loss among patients whose providers become higher propensity adopters. \nThe session will also explore the broader implications of GLP-1 adoption for healthcare utilization\, medical spending\, and health policy\, including evidence of heterogeneous impacts across patient groups. \nSpeaker: \nJasmin Moshfegh is an Assistant Professor in Economics and Public Policy at Imperial College Business School and an applied economist specializing in health economics.  \nHer research examines physician behavior\, healthcare innovation\, health inequality\, and how public policy shapes the diffusion of and access to new medical technologies. She received her PhD in Health Policy (Economics) from Stanford University in 2024 and subsequently held postdoctoral fellowships at the U.S. Department of Veterans Affairs and the National Cancer Institute at the National Institutes of Health.
URL:https://healtheconomics.org/event/weighing-the-impacts-of-glp-1s-quasi-experimental-evidence-from-provider-adoption/
LOCATION:Zoom
CATEGORIES:IHEA Event
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20260622T080000
DTEND;TZID=UTC:20260622T090000
DTSTAMP:20260609T115304
CREATED:20260604T170208Z
LAST-MODIFIED:20260608T150428Z
UID:335285-1782115200-1782118800@healtheconomics.org
SUMMARY:Preferences for care in advanced illness: new evidence from two studies in Asia
DESCRIPTION:📅 Add to Calendar!   |  🎥 Join Webinar on Zoom \nEvidence on preferences for care in advanced illness in Asia remains limited\, despite rapid ageing\, cultural diversity\, and constrained palliative care capacity. This session will feature two presentations that explore patient and family priorities\, with a view to informing person‑centered care and economic evaluation in this field. \nProf Eric Finkelstein (Duke-Singapore) will present on QCPAI (Quality of Care for Patients with Advanced Illness) – A Preference-Based Instrument to measure quality of care for patients with advanced illness in Asia Pac. [10.1016/j.vhri.2026.101620; 10.1016/j.jval.2025.05.006]. \nDr Tara Devi Laabar (University of Western Australia) will present on a discrete choice experiment on Bhutanese patients and family members to explore preferences for palliative care [10.1177/26323524251334183]. \nSpeakers: \n \nProfessor Eric Finkelstein\, PhD\, MHA  \nDr. Finkelstein is Professor of Economics at the Duke-NUS Medical School\, Singapore and the Executive Director of the Lien Centre for Palliative Care. His research focuses on the economic causes and consequences of health behaviors. A major focus are studies to better understand the complicated decisions that revolve around end-of-life care. He has published over 300 manuscripts and 2 books in these areas. Based on google scholar\, he has an h-index of 83 and his publications have been cited over 125\,000 times\, including in the landmark Supreme Court decision upholding the U.S. Affordable Care Act (aka Obamacare). He was included in the list of the World’s Most Highly Cited Researchers in 2015\, 2016 and 2017 by Thomson Reuters and Clarivate Analytics and among the Top 2% of scientists worldwide in a study by Stanford University in 2021 and 2025. \nTara Dev Laabar PhD\, MPH\, BN\, Dip GM   \nTara was a nurse educator in Bhutan. In 2015\, Tara was introduced to palliative care\, a field that was then relatively new in Bhutan. Her growing interest led her to undertake a six-week hands-on training program in palliative care at Pallium India\, Kerala\, in 2016. This experience inspired her to dedicate her career to the study\, practice\, and teaching of palliative care. \nIn 2018\, Tara moved to Australia to pursue a PhD in Palliative Care at the University of Western Australia. Her PhD research focused on developing a socially\, culturally\, and spiritually appropriate model of palliative care for Bhutan. On completion of her studies\, she returned to Bhutan\, where she contributed to palliative care advocacy\, education\, and capacity building. \nIn 2024\, due to family commitments\, Tara relocated to Perth\, Australia\, where she currently works as a Registered Nurse in residential aged care. She remains actively engaged in palliative care education\, particularly through virtual training and mentorship initiatives for healthcare professionals in LMICs. \nTara has authored and co-authored around 15 peer-reviewed publications and continues to promote equitable access to palliative care through research\, education\, and international collaboration.
URL:https://healtheconomics.org/event/preferences-for-care-in-advanced-illness-new-evidence-from-two-studies-in-asia/
LOCATION:Zoom
CATEGORIES:IHEA Event
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20260623T150000
DTEND;TZID=UTC:20260623T160000
DTSTAMP:20260609T115304
CREATED:20260602T154250Z
LAST-MODIFIED:20260609T154728Z
UID:335271-1782226800-1782230400@healtheconomics.org
SUMMARY:Health Economics Education and Application in India: Gaps and Opportunities
DESCRIPTION:📅 Add to Calendar!   |  🎥 Join Webinar on Zoom \nSpeaker: \nAndria J. N. Sirur is an Assistant Professor in Health Economics at the Manipal School of Commerce and Economics\, Manipal Academy of Higher Education (An Institute of Eminence)\, Manipal\, India. Her work focuses on health systems\, economic evaluation\, healthcare policy\, and evidence-based research to support informed decision-making in public health and healthcare management. Passionate about academic excellence and interdisciplinary collaboration\, she is committed to advancing research\, teaching\, and innovation in the field of health economics. \nJoin Dr Andria J. N. Sirur for a discussion on Health Economics Education and Application in India: Gaps and Opportunities. Despite the growing recognition of its importance\, health economics in India remains underdeveloped. Specialised training in health economics\, health systems\, and financing is scarce\, with limited undergraduate instruction and only a few graduate or certificate programmes available. Whilst there has been an acknowledgement of the pertinence of health economics within public health curricula\, there is a paucity of uniformity with regard to the depth and consistency of the relevant courses offered by different institutions. Interdisciplinary collaboration with health institutes is weak\, and international research partnerships rarely translate into stronger domestic teaching capacity. The number of professionals trained in Health Technology Assessment (HTA) – a critical component of evaluating the cost-effectiveness of medical treatments – remains limited\, with a significant proportion of research output contingent on international collaboration. A further significant challenge pertains to the absence of comprehensive health system datasets. In the absence of standardised cost data\, economic evaluation\, and evidence-based priority setting are impeded\, which in turn complicates policy decisions. The development of high-quality curricula is further hindered by shortages of qualified teaching faculty and uneven institutional capacity. Collectively\, these structural barriers impede India’s capacity to institutionalise health economics within academic training and health system governance.
URL:https://healtheconomics.org/event/health-economics-education-and-application-in-india-gaps-and-opportunities/
LOCATION:Zoom
CATEGORIES:IHEA Event
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20260629T120000
DTEND;TZID=UTC:20260629T133000
DTSTAMP:20260609T115305
CREATED:20260506T164018Z
LAST-MODIFIED:20260526T182842Z
UID:335106-1782734400-1782739800@healtheconomics.org
SUMMARY:Development Assistance for Health at a Crossroads: Navigating Aid Cuts\, Fragility\, and Financing Trade-offs for Universal Health Coverage
DESCRIPTION:📅 Add to Calendar! |   🎥 Join Webinar on Zoom \nGlobal health financing is at a turning point. With DAH projected to decline by at least 20% from 2025\, low-income and fragile states face acute risks to essential health services — from HIV and maternal health to supply chains and health information systems. \nJoin us for a webinar bringing together researchers and practitioners to explore the evidence: What do we know about the impact of DAH on health outcomes? What can country experiences like Nigeria tell us about navigating these shifts? And what financing trade-offs must be made to keep UHC within reach? \nThe Webinar will be moderated by Peter Binyaruka (Ifakara Health Institute) and will be featuring presentations by Newton Chagoma (University of Birmingham)\, Jacopo Gabani (World Bank)\, Felix Obi (Results for Development\, Nigeria)\, Sakshi Mohan (University of York)\, and Sophie Witter (Queen Margaret University\, Edinburgh). \nSpeakers \nPeter Binyaruka – Health Economist\, Ifakara Health Institute \n  \n  \n  \nNewton Chagoma – Research Fellow\, University of Birmingham \n  \n  \n  \nJacopo Gabani – World Bank\, Health Economist \n  \n  \n  \nFelix Obi – Country Director for Nigeria & Senior Program Director\, Global Health Practice\, Results for Development (R4D) \n  \n  \n  \nSakshi Mohan – Research Fellow\, Centre for Health Economics (CHE)\, University of York \n  \n  \n\nSophie Witter – Professor of International Health Financing and Health Systems\, Queen Margaret University\, Edinburgh \n 
URL:https://healtheconomics.org/event/development-assistance-for-health-at-a-crossroads-navigating-aid-cuts-fragility-and-financing-trade-offs-for-universal-health-coverage/
LOCATION:Zoom
CATEGORIES:IHEA Event
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20260716T080000
DTEND;TZID=UTC:20260716T090000
DTSTAMP:20260609T115305
CREATED:20260601T161817Z
LAST-MODIFIED:20260601T161817Z
UID:335267-1784188800-1784192400@healtheconomics.org
SUMMARY:Designing for Decisions: Practical Strategies to Improve DCE Response Quality
DESCRIPTION:📅 Add to Calendar!   |   🎥 Join Webinar on Zoom \nSpeaker:  \nAssoc Prof Alison Pearce leads the Health Economics team at the University of Sydney Daffodil Centre – a partnership with the Cancer Council NSW. She uses patient preference studies to improve cancer care by providing relevant\, reliable information for decision making. \nDr. Amber Salisbury works as a Health Economics Researcher at the University of Manchester. Her current research centres on patient preference studies that aim to support the implementation of cancer screening within the UK. \nJoin Associate Professor Alison Pearce (University of Sydney Daffodil Centre) and Dr Amber Salisbury (University of Manchester) as they share findings from a series of studies involving almost 4\,000 participants across six discrete choice experiments (DCEs). As DCEs become increasingly popular in health research\, concerns remain about participant engagement\, comprehension\, and the growing challenge of bot responses. This webinar will explore practical strategies commonly used to improve response quality—including encouraging messages\, instructional videos\, and hidden bot-detection questions—and examine whether they actually make a difference. Drawing on empirical evidence\, Alison and Amber will discuss what worked\, what didn’t\, and where researchers should focus their efforts to maximize the quality and reliability of DCE data. This session will be of interest to health economists\, preference researchers\, implementation scientists\, and anyone designing or analyzing DCEs.
URL:https://healtheconomics.org/event/designing-for-decisions-practical-strategies-to-improve-dce-response-quality/
LOCATION:Zoom
CATEGORIES:IHEA Event
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20260910T160000
DTEND;TZID=UTC:20260910T170000
DTSTAMP:20260609T115305
CREATED:20260603T171102Z
LAST-MODIFIED:20260603T171113Z
UID:335277-1789056000-1789059600@healtheconomics.org
SUMMARY:Evidence Needs for Evaluating the Cost-Effectiveness of Adult Population Genomic Screening
DESCRIPTION:📅Add to Calendar!  |   🎥 Join Webinar on Zoom \nA key promise of public health genomics is that knowledge of prevalent highly penetrant genotypes for which preventive interventions are readily available\, e.g.\, BRCA1/BRCA2 variants and Lynch syndrome\, can lead to important population health gains. However\, the fulfillment of that promise has been seriously constrained by low numbers of individuals being identified with those genotypes through risk factor-based testing. With the reduction in the cost of genomic sequencing initiatives have increasingly sought to offer sequencing to adults in high-income countries. Cost-effectiveness analyses (CEAs) have concluded that such testing is likely to be cost-effective by usual criteria. However\, the strength of evidence is low. Researchers have assessed hypothetical testing strategies and made assumptions about the uptake of testing and of preventive measures conditional on the knowledge of genomic risks. Demonstration of value for money will require accurate estimates of programmatic implementation costs\, real-world uptake of sequencing\, the frequency and timing of prophylactic practices among individuals identified through population screening initiatives\, and the effectiveness of preventive practices. The presentation will discuss several published CEAs and focus on influential explicit and implicit parameters for which empirical evidence is still needed. \nSpeaker: \nDr Scott Grosse is a health economics and outcomes researcher. \nAfter doctoral studies in public health and economics at the University of Michigan\, he joined the CDC in 1996 and retired at the end of 2024. He has co-authored roughly 300 journal articles\, many of which addressed outcomes and costs associated with newborn screening conditions and the impact of early detection. For more than a decade he was part of the Evidence-based Review Group that conducted evidence syntheses for conditions nominated for the US Recommended Uniform Screening Panel for newborn screening. In addition to his own research\, he collaborated with CDC’s Office of Public Health Genomics and Muin Khoury on seminal papers on the clinical and diagnostic utility and assessments of testing for hereditary disorders in adults. He is a member of the International Health Economics Association\, ISPOR\, the International Society for Neonatal Screening and the International Consortium on Newborn Sequencing.
URL:https://healtheconomics.org/event/evidence-needs-for-evaluating-the-cost-effectiveness-of-adult-population-genomic-screening/
LOCATION:Zoom
CATEGORIES:IHEA Event
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20260916T180000
DTEND;TZID=UTC:20260916T190000
DTSTAMP:20260609T115305
CREATED:20260526T174522Z
LAST-MODIFIED:20260526T182546Z
UID:335240-1789581600-1789585200@healtheconomics.org
SUMMARY:Anti-Racist Health Workforce Research and Policy Framework
DESCRIPTION:📅Add to Calendar!    |   🎥 Join Webinar on Zoom \nTaylor Rogers\, PhD\, will present on “Anti-Racist Health Workforce Research and Policy Framework”.  \nSpeaker: \nTaylor Rogers is a Assistant Professor of Health Policy and Management at the University of Hawaii Manoa Thompson School of Social Work and Public Health. Her research uses mixed methods to examine how structural racism shapes entry into and advancement within the population health workforce. She focuses on workforce development and retention among systematically underrepresented communities and investigates how workplace and educational inequities influence career trajectories\, policies\, and population health outcomes. \nAs a full spectrum birth and postpartum doula\, Dr. Rogers brings a practice-based perspective to her scholarship. Supporting Black families through pregnancy\, birth\, and postpartum has given her a grounded understanding of how inequities affect patients and providers alike. This practice informs her academic work and strengthens her commitment to advancing workforce strategies that are equity-driven\, culturally responsive\, community-centered\, and rooted in tradition. \nPrior to joining UH Mānoa\, Dr. Rogers was a Postdoctoral Scholar at the Healthforce Center and the Philip R. Lee Institute for Health Policy Studies at the University of California\, San Francisco.
URL:https://healtheconomics.org/event/anti-racist-health-workforce-research-and-policy-framework/
LOCATION:Zoom
CATEGORIES:IHEA Event
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20260923
DTEND;VALUE=DATE:20260925
DTSTAMP:20260609T115305
CREATED:20260512T135701Z
LAST-MODIFIED:20260512T144657Z
UID:335157-1790121600-1790294399@healtheconomics.org
SUMMARY:Croatian Health Economics Workshop (CHEW)
DESCRIPTION:The Croatian Health Economics Association is happy to announce that the 4th Croatian Health Economics Workshop (CHEW) will be held in Rovinj on 23-24 September 2026. \nThe call for abstracts is now OPEN\, with submissions welcome until the 17th May 2026. Feel free to circulate the call forward to potentially interested colleagues. \nWe look forward to receiving your submissions and seeing you in Rovinj! \nOrganising committee: Prof. Ana Bobinac\, Igor Francetić\, Ismar Velić
URL:https://healtheconomics.org/event/croatian-health-economics-workshop-chew/
LOCATION:Hotel Lone\, Rovinj\, Croatia\, Ul. Luje Adamovića 31\, 52210\, Rovinj\, Croatia\, Croatia (Local Name: Hrvatska)
CATEGORIES:External Event
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=UTC:20260923T110000
DTEND;TZID=UTC:20260923T121500
DTSTAMP:20260609T115305
CREATED:20260507T202740Z
LAST-MODIFIED:20260608T144456Z
UID:335151-1790161200-1790165700@healtheconomics.org
SUMMARY:Health Inequality Aversion in Asia - Early Findings\, Methodological Challenges and Next Steps
DESCRIPTION:📅 Add to Calendar! |  🎥 Join Webinar on Zoom \nBackground: \nEquity in health has been a concern for long and has been central to aspirations for Universal Health Coverage (UHC)\, an objective enshrined in the Sustainable Development Goals (SDGs). Health Technology Assessment (HTA) has been identified as an approach to support UHC by use of evidence to inform policy on allocation of resources for health\, taking equity and other relevant considerations into account. Equity has featured in health economic research using various methodological approaches and over the past decade\, there have been innovations in methodological approaches to address equity through health economic evaluations\, such as Distributional Cost-effectiveness Analysis (DCEA) and Extended Cost-effectiveness Analysis (ECEA). \nThe Equity Informative Economic Evaluation Special Interest Group (SIG) of the the International Health Economics Association (iHEA) seeks to provide a platform for researchers and “encourage the development and synthesis of methods for using economic evaluation to address equity concerns”. More information is available at the following link: https://healtheconomics.org/sigs/eee/ \nTo further this mandate\, the EIEE SIG proposes hosting a series of webinars spanning the next two years. \nObjectives of the series: \n· To learn and share about equity informative health economic evaluations \n· To connect researchers working on equity informative health economic evaluations and form partnerships \n· To identify potential areas for future research and collaboration on equity informative health economic evaluations \n  \nThe first of the webinar series is: Health Inequality Aversion in Asia – Early Findings\, Methodological Challenges and Next Steps\, with the aim to: \n· To share findings from studies conducted on inequity \n· To learn about methodological challenges and potential applications \n· To identify potential areas for collaboration \nSpeakers: \n \nDr. Xiaoning He is an Associate Professor and Doctoral Supervisor at the School of Pharmaceutical Science and Technology\, Tianjin University.  \nShe was a visiting scholar at the University of Sheffield\, UK\, from September 2019 to March 2020. Her research interests cover pharmacoeconomics\, real-world evidence studies\, and health policy evaluation. She has served as the Principal Investigator (PI) for the General Program and Youth Program of the National Natural Science Foundation of China\, as well as for the General Program and Youth Program of the Tianjin Natural Science Foundation. Additionally\, she acts as a sub-project leader for the Major Program of the National Social Science Fund of China. She has authored more than 70 peer-reviewed journal articles\, among which over 40 are indexed in SCI/SSCI\, published in reputable journals including Value in Health and Pharmacoeconomics. She also contributed to the compilation of the China Guidelines for Pharmacoeconomic Evaluation 2025. She serves as Member and Secretary of the Pharmacoeconomics Committee of the Chinese Pharmaceutical Association\, Standing Committee Member of the Pharmacoeconomics Committee of the China Health Insurance Research Association\, and Member and Secretary of the Pharmacoeconomics Committee of the Tianjin Pharmaceutical Association. \n \nDr. Sitanshu Sekhar Kar is a Professor in the Department of Preventive and Social Medicine\, Jawaharlal Institute of Postgraduate Medical Education and Research (JIPMER)\, Puducherry.  \nHis areas of interest are Epidemiology\, NCD prevention & Health Promotion\, Health System Strengthening\, and Medical Education. He is leading the distributional cost-effective analysis study in India. He is passionate about capacity strengthening of early career researchers and led the inaugural programme through HTAsiaLink. He has contributed to the research community and was the Chief Editor of the International Journal of Medicine and Public Health (2013-2015)\, and a member of the Editorial Board of the Indian Journal of Community & Family Medicine and NTTC Bulletin. He is a reviewer of many national and international peer-reviewed journals like BMC Health\, Health Promotion International\, International Journal of Medicine and Public Health\, Indian Journal of Community Health\, IJOEM\, IJMS\, Journal of Pharmacology and Therapeutics & Indian Journal of Public Health. \n \nDr. Wanrudee Isaranuwatchai\, Secretary General and Senior Researcher of the Health Intervention and Technology Assessment Program Foundation (HITAP)\, Thailand and Affiliated Scientist at St. Michael’s Hospital\, and an Associate Professor at the Institute of Health Policy\, Management and Evaluation\, University of Toronto\, in Canada. \nHer research focuses on how to apply health economics and health technology assessment (HTA) in the real-world setting as well as how to advance methods in economic evaluation (EE). She has experience conducting EEs using various methods with specific interest in the potential of big data in health economics and HTA to support evidence generation and policy-making process. \nShe has also collaborated with researchers\, health professionals\, and policy-makers in various areas to help communicate the value of health initiatives using EE. She has contributed to the training on HTA to support health systems in Asia\, Africa\, and North America. Dr. Isaranuwatchai is dedicated to the creation and use of evidence in healthcare decision making. \n \nDr. Stéphane Verguet is an Associate Professor of Global Health in the Department of Global Health and Population at the Harvard T.H. Chan School of Public Health and a core faculty member of Harvard University’s Center for Health Decision Science.  \nHis research concerns health systems\, health economics\, and priority setting\, with significant contributions toward incorporating dimensions of equity into the economic evaluation of health policies and priority setting through the modeling of health benefit packages and intersectoral interventions\, via applied economic evaluations. He has co-chaired the Analytics & Metrics Community of Practice of the Research Consortium for School Health & Nutrition since 2021 and has contributed to the World Bank’s Disease Control Priorities since 2009\, most recently as a lead editor for the Universal Health Coverage volume of its fourth edition. He was also a Commissioner of The Lancet Global Health 2050 Commission. Verguet has degrees from the University of California\, Berkeley\, and the École Polytechnique and was previously on the faculty of the University of Washington. \n \nDr. Richard Cookson is a Professor at the Centre for Health Economics\, and Co-Director of the Equity in Health Policy (Equipol) research group. \nHe has helped pioneer “equity-informative” methods of policy analysis\, including distributional cost-effectiveness analysis; health equity indicators for healthcare quality assurance; and methods for investigating public concern for reducing health inequality; and is currently developing microsimulation methods for long-term childhood policy analysis.  He has co-chaired international working groups on equity\, worked in the UK Prime Minister’s Delivery Unit and served on various NHS advisory committees including the National Institute for Health and Care Excellence and the NHS Advisory Committee on Resource Allocation. Richard’s research focuses on equity in health and health care. Richard is an Honorary Public Health Academic\, Office for Health Improvement and Disparities. He has co-chaired various international working groups on equity; served on various NHS advisory groups including the National Institute for Health and Clinical Excellence (NICE) Technology Appraisal Committee 2002-7\, the Public Health Interventions Advisory Committee 2007-9\, the NHS Outcomes Framework Technical Advisory Committee 2012-16 and the NHS Advisory Committee for Resource Allocation 2017-21; and was seconded to the Prime Minister’s Delivery Unit in the Treasury in 2010. Richard holds a BA in Politics\, Philosophy and Economics and a DPhil in Economics from the University of York\, and an MPhil in Economics from the University of Oxford. \nResources\n\nHealth technology assessment – Global\nSelected\n\n\n\n\n\n\nWHO resolution 67.23 – Health intervention and technology assessment in support of universal health coverage\nSEA/RC66/R4 – Health intervention and technology assessment in support of universal health coverage\n\n\n\n\n\n\nO’Rourke B\, Oortwijn W\, Schuller T. The new definition of health technology assessment: A milestone in international collaboration. International journal of technology assessment in health care. 2020 Jun;36(3):187-90.\nDistributional cost-effectiveness analysis (DCEA) – Centre for Health Economics\, University of York\nTutorial: Extended Cost-Effectiveness Analysis
URL:https://healtheconomics.org/event/health-inequality-aversion-in-asia-early-findings-methodological-challenges-and-next-steps/
LOCATION:Zoom
CATEGORIES:IHEA Event
END:VEVENT
END:VCALENDAR